Literature DB >> 21505111

Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia.

Dilip V Jeste1, Owen M Wolkowitz, Barton W Palmer.   

Abstract

Aging is not a uniform process. In the general population, there is a paradox of aging: age-associated decline in physical and some cognitive functions stands in contrast to an enhancement of subjective quality of life and psychosocial functioning. This paradox is even more striking in people with schizophrenia. Compared with the overall population, individuals with schizophrenia have accelerated physical aging (with increased and premature medical comorbidity and mortality) but a normal rate of cognitive aging, although with mild cognitive impairment starting from premorbid period and persisting throughout life. Remarkably, psychosocial function improves with age, with diminished psychotic symptoms, reduced psychiatric relapses requiring hospitalization and better self-management. Many older adults with schizophrenia successfully adapt to the illness, with increased use of positive coping techniques, enhanced self-esteem and increased social support. Although complete remission is uncommon, most individuals with schizophrenia experience significant improvement in their quality of well-being. Cohort effect and survivor bias may provide a partial explanation for this phenomenon. However, the improvement also may reflect some brain changes that are beneficial for the course of schizophrenia along with neuroplasticity of aging. The proposed hypothesis has several implications. As significant medical morbidity in schizophrenia takes years to develop, studies of changes in sensitive biomarkers of aging during the course of illness may point to new treatments aimed at normalizing the rate of biological aging in schizophrenia. At the same time, effective psychotherapeutic interventions can affect brain structure and function and produce lasting positive behavioral changes in aging adults with schizophrenia.
© The Author 2011. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21505111      PMCID: PMC3080682          DOI: 10.1093/schbul/sbr026

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  23 in total

1.  Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms.

Authors:  Hua Jin; David Folsom; Alana Sasaki; Sunder Mudaliar; Robert Henry; Monique Torres; Shah Golshan; Danielle K Glorioso; Dilip Jeste
Journal:  Schizophr Res       Date:  2010-11-19       Impact factor: 4.939

Review 2.  Psychological and metabolic stress: a recipe for accelerated cellular aging?

Authors:  Elissa S Epel
Journal:  Hormones (Athens)       Date:  2009 Jan-Mar       Impact factor: 2.885

3.  A snapshot of the age distribution of psychological well-being in the United States.

Authors:  Arthur A Stone; Joseph E Schwartz; Joan E Broderick; Angus Deaton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients.

Authors:  P D Harvey; J M Silverman; R C Mohs; M Parrella; L White; P Powchik; M Davidson; K L Davis
Journal:  Biol Psychiatry       Date:  1999-01-01       Impact factor: 13.382

5.  Stability and course of neuropsychological deficits in schizophrenia.

Authors:  R K Heaton; J A Gladsjo; B W Palmer; J Kuck; T D Marcotte; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  2001-01

Review 6.  Is schizophrenia a syndrome of accelerated aging?

Authors:  Brian Kirkpatrick; Erick Messias; Philip D Harvey; Emilio Fernandez-Egea; Christopher R Bowie
Journal:  Schizophr Bull       Date:  2007-12-21       Impact factor: 9.306

Review 7.  What do we know about neuropsychological aspects of schizophrenia?

Authors:  Barton W Palmer; Sharron E Dawes; Robert K Heaton
Journal:  Neuropsychol Rev       Date:  2009-07-30       Impact factor: 7.444

8.  Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.

Authors:  Stéphane Potvin; Emmanuel Stip; Amir A Sepehry; Alain Gendron; Ramatoulaye Bah; Edouard Kouassi
Journal:  Biol Psychiatry       Date:  2007-11-19       Impact factor: 13.382

9.  Premorbid IQ in schizophrenia: a meta-analytic review.

Authors:  Kristen A Woodberry; Anthony J Giuliano; Larry J Seidman
Journal:  Am J Psychiatry       Date:  2008-04-15       Impact factor: 18.112

10.  Physical and mental health-related quality of life among older people with schizophrenia.

Authors:  David P Folsom; Colin Depp; Barton W Palmer; Brent T Mausbach; Shahrokh Golshan; Ian Fellows; Veronica Cardenas; Thomas L Patterson; Helena C Kraemer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2009-01-24       Impact factor: 4.939

View more
  55 in total

1.  Thought, language, and communication deficits and association with everyday functional outcomes among community-dwelling middle-aged and older adults with schizophrenia.

Authors:  Anjana Muralidharan; Anastasia Finch; Christopher R Bowie; Philip D Harvey
Journal:  Schizophr Res       Date:  2017-08-01       Impact factor: 4.939

2.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

3.  Comorbidity profile and healthcare utilization in elderly patients with serious mental illnesses.

Authors:  Hugh C Hendrie; Donald Lindgren; Donald P Hay; Kathleen A Lane; Sujuan Gao; Christianna Purnell; Stephanie Munger; Faye Smith; Jeanne Dickens; Malaz A Boustani; Christopher M Callahan
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

4.  Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder.

Authors:  Tanya T Nguyen; Tomasz Kosciolek; Lisa T Eyler; Rob Knight; Dilip V Jeste
Journal:  J Psychiatr Res       Date:  2018-01-31       Impact factor: 4.791

Review 5.  Overview of measurement-based positive psychiatry.

Authors:  Graham M L Eglit; Barton W Palmer; Dilip V Jeste
Journal:  Nord J Psychiatry       Date:  2018-08       Impact factor: 2.202

Review 6.  Psychiatric disorders and leukocyte telomere length: Underlying mechanisms linking mental illness with cellular aging.

Authors:  Daniel Lindqvist; Elissa S Epel; Synthia H Mellon; Brenda W Penninx; Dóra Révész; Josine E Verhoeven; Victor I Reus; Jue Lin; Laura Mahan; Christina M Hough; Rebecca Rosser; F Saverio Bersani; Elizabeth H Blackburn; Owen M Wolkowitz
Journal:  Neurosci Biobehav Rev       Date:  2015-05-18       Impact factor: 8.989

7.  Neurocognitive and functional correlates of mobile phone use in middle-aged and older patients with schizophrenia.

Authors:  Colin A Depp; Alexandrea L Harmell; Ipsit V Vahia; Brent T Mausbach
Journal:  Aging Ment Health       Date:  2015-03-13       Impact factor: 3.658

8.  Positive light on schizophrenia and aging: Commentary on course and predictors of symptomatic remission in schizophrenia: A 5-year follow-up study in a Dutch psychiatric catchment area, by Lange et al.

Authors:  Tanya T Nguyen; Dilip V Jeste
Journal:  Schizophr Res       Date:  2019-08-01       Impact factor: 4.939

9.  Mild Neurocognitive Disorder: A Model for Accelerated Biological Aging?

Authors:  Dilip V Jeste; Barton W Palmer
Journal:  Am J Geriatr Psychiatry       Date:  2016-08-25       Impact factor: 4.105

10.  Paradoxical Trend for Improvement in Mental Health With Aging: A Community-Based Study of 1,546 Adults Aged 21-100 Years.

Authors:  Michael L Thomas; Christopher N Kaufmann; Barton W Palmer; Colin A Depp; Averria Sirkin Martin; Danielle K Glorioso; Wesley K Thompson; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2016-08       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.